Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-15738 |
Brand: | MCE |
CAS: | 778277-15-9 |
MDL | MFCD16877246 |
---|---|
Molecular Weight | 418.37 |
Molecular Formula | C20H17F3N4O3 |
SMILES | FC(F)(F)OC(C=C1)=CC=C1NC2=NC=NC(C3=CC=CC(C(NCCO)=O)=C3)=C2 |
GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC 50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer [1] [2] .
IC50: 0.22 µM (Abl) [1]
GNF-5 has inhibition of wild-type Abl with an IC 50 value of 0.22 µM but no inhibition for myristate site mutant E505K (IC 50 >10 µM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | wild type and mutant Bcr-Abl expressing Ba/F3 cells |
Concentration: | 0.2, 0.8 and 1.6 μM |
Incubation Time: | 48 h |
Result: | Inhibited wild-type Abl in a non-ATP competitive fashion. |
GNF-5 (5 mg/kg iv. or 20 mg/kg oral) has suitable pharmacokinetic parameters
[1]
.
GNF-5 (oral, 50 or 100 mg/kg, twice daily, for 7 days) shows efficacious in vivo but can observe relapses
[1]
.
GNF-5 (75 mg/kg, b.i.d) inhibits T315I Bcr-Abl combination with nilotinib in vivo
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male Balb/c mice [1] | ||||||||||||||||
Dosage: | 5 mg/kg, 20 mg/kg | ||||||||||||||||
Administration: | 5 mg/kg intravenously or 20 mg/kg orally | ||||||||||||||||
Result: |
|
Animal Model: | p210 xenograft model [1] |
Dosage: | 50 or 100 mg/kg |
Administration: | oral, twice daily, for 7 days |
Result: | Could normalize blood counts and spleen size. |
Animal Model: | Bone marrow transduction/transplantation model [1] |
Dosage: | 75 mg/kg |
Administration: | twice daily |
Result: |
Showed no significant response (alone).
Showed no toxicity and had a strong and sustained inhibition of Bcr-Abl-mediated signaling combination with nilotinib. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 49 mg/mL ( 117.12 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.3902 mL | 11.9511 mL | 23.9023 mL |
5 mM | 0.4780 mL | 2.3902 mL | 4.7805 mL |
10 mM | 0.2390 mL | 1.1951 mL | 2.3902 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.